{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T21:48:03Z","timestamp":1788299283461,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Innovation of Science and Technology"},{"name":"Fujian province","award":["2016Y9037"],"award-info":[{"award-number":["2016Y9037"]}]},{"name":"Health and Education of Fujian Province","award":["WKJ2016-2-34"],"award-info":[{"award-number":["WKJ2016-2-34"]}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2016J05190"],"award-info":[{"award-number":["2016J05190"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fujian Medical University","award":["2015MP035"],"award-info":[{"award-number":["2015MP035"]}]},{"name":"Scientific Research Personnel Training Project for Health"},{"name":"Family Planning of Fujian Province","award":["2016-1-34"],"award-info":[{"award-number":["2016-1-34"]}]},{"name":"Youth Research Project of Fujian Provincial Department of Education","award":["JAT160213"],"award-info":[{"award-number":["JAT160213"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA205153"],"award-info":[{"award-number":["R01CA205153"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.canlet.2018.12.010","type":"journal-article","created":{"date-parts":[[2018,12,22]],"date-time":"2018-12-22T00:47:04Z","timestamp":1545439624000},"page":"82-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"special_numbering":"C","title":["Pin1 inhibition reverses the acquired resistance of human hepatocellular carcinoma cells to Regorafenib via the Gli1\/Snail\/E-cadherin pathway"],"prefix":"10.1016","volume":"444","author":[{"given":"Jichuang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxian","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hekun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao Zhen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0734-1567","authenticated-orcid":false,"given":"Kun Ping","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2018.12.010_bib1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics","volume":"65","author":"Torre","year":"2012","journal-title":"Ca - Cancer J. Clin."},{"key":"10.1016\/j.canlet.2018.12.010_bib2","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1053\/j.gastro.2016.11.048","article-title":"Liver cancer cell of origin, molecular class, and effects on patient prognosis","volume":"152","author":"Sia","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2018.12.010_bib3","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2018.12.010_bib4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nrgastro.2017.7","article-title":"Liver cancer: Regorafenib as second-line therapy in hepatocellular carcinoma","volume":"14","author":"Duffy","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.canlet.2018.12.010_bib5","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.3390\/ijms19051518","article-title":"Chlorogenic acid improves the Regorafenib effects in human hepatocellular carcinoma cells","volume":"19","author":"Refolo","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2018.12.010_bib6","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","article-title":"EMT, CSCs, and drug resistance: the mechanistic link and clinical implications","volume":"14","author":"Shibue","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2018.12.010_bib7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.canlet.2016.08.017","article-title":"TUFT1 regulates metastasis of pancreatic cancer through HIF1-Snail pathway induced epithelial-mesenchymal transition","volume":"382","author":"Zhou","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2018.12.010_bib8","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1172\/JCI38019","article-title":"Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease","volume":"119","author":"Acloque","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2018.12.010_bib9","doi-asserted-by":"crossref","first-page":"698","DOI":"10.2174\/1568009617666170427104356","article-title":"Epithelial-to-Mesenchymal transition: a mediator of sorafenib resistance in advanced hepatocellular carcinoma","volume":"17","author":"Mir","year":"2017","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.canlet.2018.12.010_bib10","doi-asserted-by":"crossref","first-page":"e2201","DOI":"10.1038\/cddis.2015.324","article-title":"Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK\/PI3K\/AKT signaling","volume":"7","author":"Zhang","year":"2016","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2018.12.010_bib11","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jhep.2010.12.043","article-title":"Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations","volume":"55","author":"Chen","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.canlet.2018.12.010_bib12","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.canlet.2015.10.012","article-title":"TMPRSS4 induces cancer stem cell-like properties in lung cancer cells and correlates with ALDH expression in NSCLC patients","volume":"370","author":"de Aberasturi","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2018.12.010_bib13","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.pharmthera.2017.08.009","article-title":"EMT: mechanisms and therapeutic implications","volume":"182","author":"Singh","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.canlet.2018.12.010_bib14","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1158\/0008-5472.CAN-13-2785","article-title":"Prolyl isomerase Pin1 acts downstream of miR200c to promote cancer stem\u2013like cell traits in breast cancer","volume":"74","author":"Luo","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2018.12.010_bib15","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.celrep.2015.03.002","article-title":"The Rab2A GTPase promotes breast cancer stem cells and tumorigenesis via Erk signaling activation","volume":"11","author":"Luo","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2018.12.010_bib16","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nm.3839","article-title":"Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer","volume":"21","author":"Wei","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2018.12.010_bib17","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrc.2016.49","article-title":"The isomerase PIN1 controls numerous cancer-driving pathways and is a unique drug target","volume":"16","author":"Zhou","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2018.12.010_bib18","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.1038\/onc.2017.137","article-title":"Prolyl isomerase PIN1 regulates the stability, transcriptional activity and oncogenic potential of BRD4","volume":"36","author":"Hu","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2018.12.010_bib19","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1093\/mp\/sst076","article-title":"Phosphatidic acid (PA) binds PP2AA1 to regulate PP2A activity and PIN1 polar localization","volume":"6","author":"Gao","year":"2013","journal-title":"Mol. Plant"},{"key":"10.1016\/j.canlet.2018.12.010_bib20","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2174\/1566524016666161124103654","article-title":"The roles of the unique prolyl isomerase Pin1 in cancer-related viral and bacterial infections","volume":"15","author":"Wang","year":"2016","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.canlet.2018.12.010_bib21","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/hep.29819","article-title":"Targeting Pin1 by inhibitor API-1 regulates microRNA biogenesis and suppresses hepatocellular carcinoma development","volume":"68","author":"Pu","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2018.12.010_bib22","doi-asserted-by":"crossref","first-page":"9921","DOI":"10.3748\/wjg.v22.i45.9921","article-title":"Understanding the role of PIN1 in hepatocellular carcinoma","volume":"22","author":"Cheng","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.canlet.2018.12.010_bib23","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1006\/bbrc.1999.1736","article-title":"Mice lacking Pin1 develop normally, but are defective in entering cell cycle from G(0) arrest","volume":"265","author":"Fujimori","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.canlet.2018.12.010_bib24","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.tibs.2011.07.001","article-title":"Prolyl isomerase Pin1 as a molecular switch to determine the fate of phosphoproteins","volume":"36","author":"Liou","year":"2011","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.canlet.2018.12.010_bib25","doi-asserted-by":"crossref","first-page":"43639","DOI":"10.1038\/srep43639","article-title":"Chemical or genetic Pin1 inhibition exerts potent anticancer activity against hepatocellular carcinoma by blocking multiple cancer-driving pathways","volume":"7","author":"Liao","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2018.12.010_bib26","doi-asserted-by":"crossref","first-page":"45915","DOI":"10.1038\/srep45915","article-title":"MicroRNA-140-5p inhibits hepatocellular carcinoma by directly targeting the unique isomerase Pin1 to block multiple cancer-driving pathways","volume":"7","author":"Yan","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2018.12.010_bib27","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jconrel.2017.11.031","article-title":"A novel controlled release formulation of the Pin1 inhibitor ATRA to improve liver cancer therapy by simultaneously blocking multiple cancer pathways","volume":"269","author":"Yang","year":"2018","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.canlet.2018.12.010_bib28","doi-asserted-by":"crossref","first-page":"29771","DOI":"10.18632\/oncotarget.15967","article-title":"Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma","volume":"8","author":"Zheng","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2018.12.010_bib29","doi-asserted-by":"crossref","first-page":"15773","DOI":"10.1038\/ncomms15773","article-title":"EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells","volume":"8","author":"Neelakantan","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2018.12.010_bib30","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.canlet.2016.02.053","article-title":"PCAF inhibits hepatocellular carcinoma metastasis by inhibition of epithelial-mesenchymal transition by targeting Gli-1","volume":"375","author":"Li","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2018.12.010_bib31","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/ncb0901-793","article-title":"Pin1 regulates turnover and subcellular localization of \u03b2-catenin by inhibiting its interaction with APC","volume":"3","author":"Ryo","year":"2001","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.canlet.2018.12.010_bib32","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S1097-2765(03)00490-8","article-title":"Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65\/RelA","volume":"12","author":"Ryo","year":"2003","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2018.12.010_bib33","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/onc.2016.247","article-title":"FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation","volume":"36","author":"Tong","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2018.12.010_bib34","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/cr.2014.109","article-title":"Prolyl isomerase Pin1 in cancer","volume":"24","author":"Lu","year":"2014","journal-title":"Cell Res."},{"key":"10.1016\/j.canlet.2018.12.010_bib35","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-018-0611-7","article-title":"Pin1 inhibition exerts potent activity against acute myeloid leukemia through blocking multiple cancer-driving pathways","volume":"11","author":"Lian","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2018.12.010_bib36","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/bjc.2015.272","article-title":"Pin1 facilitates NF-\u03baB activation and promotes tumour progression in human hepatocellular carcinoma","volume":"113","author":"Shinoda","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2018.12.010_bib37","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/32433","article-title":"A causal role for E-cadherin in the transition from adenoma to carcinoma","volume":"392","author":"Perl","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2018.12.010_bib38","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/cncr.20946","article-title":"Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma","volume":"103","author":"Elloul","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2018.12.010_bib39","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/jcp.25206","article-title":"Involvement of notch-1 in resistance to Regorafenib in colon cancer cells","volume":"231","author":"Mirone","year":"2016","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.canlet.2018.12.010_bib40","doi-asserted-by":"crossref","first-page":"15772","DOI":"10.1038\/ncomms15772","article-title":"A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action","volume":"8","author":"Campaner","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2018.12.010_bib41","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1002\/art.39741","article-title":"Pin1-targeted therapy against systemic lupus erythematosus","volume":"68","author":"Wei","year":"2016","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.canlet.2018.12.010_bib42","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1038\/s41467-018-03886-6","article-title":"The IL-33-PIN1-IRAK-M axis is critical for type 2 immunity in IL-33-induced allergic airway inflammation","volume":"9","author":"Nechama","year":"2018","journal-title":"Nat. Commun."}],"updated-by":[{"DOI":"10.1016\/j.canlet.2024.217257","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000}}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383518307250?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383518307250?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T20:28:55Z","timestamp":1729110535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383518307250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":42,"alternative-id":["S0304383518307250"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2018.12.010","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.canlet.2024.217257","asserted-by":"object"}]},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pin1 inhibition reverses the acquired resistance of human hepatocellular carcinoma cells to Regorafenib via the Gli1\/Snail\/E-cadherin pathway","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2018.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}